Ethical dilemmas encountered during clinical drug trials

International Journal of Antimicrobial Agents

Volumn 24, Issue 1, 2004, Pages 24-31

  Daikos, George K ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Active controls; Clinical trials; Ethics; Placebo

Indexed keywords

ANTIBIOTIC AGENT; PLACEBO;

CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; HEALTH SERVICE; HEALTH SURVEY; HUMAN; INFECTION PREVENTION; INFORMED CONSENT; POLICY; PRIORITY JOURNAL; REVIEW; SYPHILIS;

EID: 3042551699     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.03.004     Document Type: Note

References (57)

1. Hippocrates. Parangeliai (Recommendations, Precepts) 2 Hippocrates 1. Loeb Classical Library. Harvard University Press; 1984. p. 314.
2. Lind J. A treatise of the scurvy, London, A. Millar 1753. Cited by F.G. Lepreau. N. Engl. J. Med. 347:2002;692
3. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948;769-82.
4. Wolinsky H. Steps still being taken to undo damage of 'America's Nüremberg'. Ann. Intern. Med. 127:1997;I43-I44
5. Rockwell D.H., Yobss A.R., Moore M.B. The Tuskegee study of untreated syphilis. The 30th year of observation. Arch. Intern. Med. 114:1964;792-794
6. Jones J. Bad blood. The Tuskegee syphilis experiment. Free Press; 1993.
7. Global Forum for Health Research. The 10/90 report on health research. Geneva, Switzerland, 1999.
8. Bodenheimer T. Uneasy alliance, clinical investigators and the pharmaceutical industry. N. Engl. J. Med. 342:2000;1539-1544
9. Lo B., Wolf L.E., Berkeley A. Conflict-of-interest policies for investigators in clinical trials. N. Engl. J. Med. 343:2000;1616-1620
10. McCrary van S., Anderson C.B., Jakovljevic R.S., et al. A national survey of policies on disclosure of conflicts of interest in biomedical research. N. Engl. J. Med. 343:2000;1621-1626
11. Drazen J.M., Koski G. To protect those who serve. N. Engl. J. Med. 343:2000;1643-1645
12. Martin J.B., Kasper D.L. In whose best interest? Breaching the academic industrial wall. N. Engl. J. Med. 343:2000;1646-1649
13. Willman D. Stealth merger: drug companies and government research. Los Angeles Times December 7, 2003. p. A1.
14. Drazen J.M., Curfman G.D. Financial associations of authors. N. Engl. J. Med. 346:2002;1901-1902
15. James A., Horton R. The Lancet's policy on conflicts of interest. Lancet. 361:2003;8-9
16. James A., Horton R., Collingridge D., et al. The Lancet's policy on conflicts of interest. Lancet. 363:2004;2-3
17. Steinbrook R. Financial conflicts of interest and the NIH. N. Engl. J. Med. 305:2004;327-330
18. Nathan D.G., Weatherall D.J. Academia and industry: lessons from the unfortunate events in Toronto. Lancet. 353:1999;771-772
19. Shuchman M. Consequences of blowing the whistle in medical research. Ann. Intern. Med. 132:2000;1013-1015
20. Weatherall D. Academia and industry: increasingly uneasy bedfellows. Lancet. 355:2000;1574
21. Sponsorship, authorship and accountability. N Engl J Med 2001;345:825-7 [Editorial].
22. Ioannidis J.P.A., Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. J. Am. Med. Assoc. 285:2001;437-443
23. Safeguarding participants in clinical trials. Lancet 2000;355:2177 [Editorial].
24. Department of Health and Human Services. Recruiting human subjects: pressures in industry-sponsored clinical research. Washington, DC, 2000.
25. Larkin M. Clinical trials: what price progress? Lancet. 354:1999;1534
26. Angell M. Is academic medicine for sale? N. Engl. J. Med. 342:2000;1516-1518. [Editorial]
27. Giannakis I.A., Ioannidis J.P.A. Arabian nights 1001 tales of how pharmaceutical companies cater to the material needs of doctors: a case report. Br. Med. J. 321:2000;1563-1564
28. Drazen J.M. Institutions, contracts and academic freedom. N. Engl. J. Med. 347:2002;1362-1363
29. Pellegrino E.D. The Nazi doctors and Nüremberg: some moral lessons revisited. Ann. Intern. Med. 127:1997;307-308
30. Quinn T.C., Wawer M.J., Sewankambo N., et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N. Engl. J. Med. 342:2000;921-929
31. Angell M. Investigators' responsibilities for human subjects in developing countries. N. Engl. J. Med. 342:2000;967-969
32. Shapiro H.T., Meslin E.M. Ethical issues in the design and conduct of clinical trials in developing countries. N. Engl. J. Med. 345:2001;139-141
33. Koski G., Nightingale S.L. Research involving human subjects in developing countries. N. Engl. J. Med. 345:2001;136-138
34. Pocock S.J., Elbourne D.R. Randomized trials or observational tribulations? N. Engl. J. Med. 342:2000;1907-1909
35. Benson K., Hartz A.J. A comparison of observational studies and randomised, controlled trials. N. Engl. J. Med. 342:2000;1878-1886
36. Concato J., Shah N., Horwitz R.I. Randomized, controlled trials, observational studies, and their hierarchy of research decisions. N. Engl. J. Med. 342:2000;1887-1892
37. Rothman K., Michels K.B. The continuing unethical use of placebo controls. N. Engl. J. Med. 331:1994;394-398
38. Temple R., Ellenberg S.S. Placebo-controlled trials and active control trials in the evaluation of new treatments. Part 1. Ethical and scientific issues. Ann. Intern. Med. 133:2000;455-463
39. Ellenberg S.S., Temple R. Placebo-controlled trials and active control trials in the evaluation of new treatments. Part 2. Practical issues and specific cases. Ann. Intern. Med. 133:2000;464-470
40. Simon R. Are placebo-controlled clinical trials ethical or needed when alternative treatment exists? Ann. Intern. Med. 133:2000;474-475. [Editorial]
41. Reynolds T. The ethics of placebo-controlled trials. Ann. Intern. Med. 133:2000;491-492
42. Lee T.H. "Me-too" products - friend or foe? N. Engl. J. Med. 350:2004;221-222
43. Edwards S., Lilford R., Braunholz D., Jackson J., Hewison J., Thornton J. Ethical issues in the design and conduct of randomised controlled trials. Health Tech. Assess. 2:1998;1-132
44. Djulbegovic B. Placebo-controlled trials. Ann. Intern. Med. 135:2001;62-63
45. Kaptchuk T.J. Powerful placebo: the dark side of the randomised control trial. Lancet. 351:1998;1722-1725
46. Huston P., Peterson R. Withholding proven treatment in clinical research. N. Engl. J. Med. 345:2001;912-914
47. Emanuel E.J., Miller F.G. The ethics of placebo-controlled trials. A middle ground. N. Engl. J. Med. 345:2001;915-919
48. Joffe S., Cook F.E., Cleary P.D., et al. Quality of informed consent in cancer clinical trials, a cross-sectional survey. Lancet. 358:2001;1772
49. Morris R.H. Thriving with CML. Lancet. 358(Suppl.):2001;S12
50. Truog R.D., Robinson W., Randolph A., Morris A. Is informed consent always necessary for randomised controlled trials? N. Engl. J. Med. 340:1999;804-808
51. Wendler D., Prasad K. Core safeguards for clinical research with adults who are unable to consent. Ann. Intern. Med. 135:2001;514-523
52. Shalala D. Protecting research subjects - what must be done. N. Engl. J. Med. 343:2000;808-810
53. Steinbrook R. Protecting research subjects - the crisis at John Hopkins. N. Engl. J. Med. 346:2002;716-720
54. How consumers can and should improve clinical trials. Lancet 2001;357:1721 [Editorial].
55. Hippocrates. Epidemics 1st 11. Hippokratic Writings. London: Penguin Classics; 1978. p. 93-4.
56. Stephens G.G. Minding others' bodies: the golden rule in medical practice. Humane Med. 6:1990;255-259
57. Oreopoulos D.G. Compassion and mercy in the practice of medicine. Humane Health Care. 1:2001;1